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Abstract  
Aims: Paediatric low-grade gliomas (pLGGs) are a heterogeneous group of brain tumours 
associated with a high overall survival: however, they are prone to recur and supratentorial 
lesions are difficult to resect, being associated with high percentage of disease recurrence. Our 
aim was to shed light on the biology of pLGGs. 
 
Methods: We performed microRNA profiling on 45 fresh-frozen grade I tumour samples of various 
histological classes, resected from patients aged ≤ 16 years. We identified 93 microRNAs specifically 
dysregulated in tumours as compared to non-neoplastic brain tissue. Pathway analysis of the 
microRNAs signature revealed PI3K/AKT signalling as one of the centrally enriched oncogenic 
signalling. To date, activation of the PI3K/AKT pathway in pLGGs has been reported, although 
activation mechanisms have not been fully investigated yet.  
 
Results: One of the most markedly down-regulated microRNAs in our supratentorial pLGGs cohort 
was miR-139-5p, whose targets include the gene encoding the PI3K’s (phosphatidylinositol 3-kinase) 
catalytic unit, PIK3CA. We investigated the role of miR-139-5p in regulating PI3K/AKT signalling by 
the use of human cell cultures derived from supratentorial pLGGs. MiR-139-5p overexpression 
inhibited pLGG cell proliferation and decreased the phosphorylation of PI3K target AKT and p70 S6K, 
a hallmark of PI3K/AKT/mTORC1 signalling activation. The effect of miR-139-5p was mediated by 
PI3K inhibition, as suggested by the decrease in proliferation and phosphorylation of AKT and p70 
S6K after treatment with the direct PI3K inhibitor LY294002.  
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Conclusions: These findings provide the first evidence that down-regulation of miR-139-5p in 
supratentorial pLGG drives cell proliferation by de-repressing PI3K/AKT signalling.  
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Introduction  
The most commonly diagnosed brain tumours in children are low-grade gliomas (LGGs). 
Paediatric LGGs (pLGGs) include different entities, as defined by the revised World Health 
Organization (WHO) Classification of Central Nervous System (CNS) Tumours, which is based on both 
histological and molecular features [1]. The vast majority of pLGGs are pilocytic astrocytomas (PAs), 
and they are the ones that have been studied most thoroughly. These tumours are driven by 
dysregulated signalling through the MAPK/ERK pathway [2]. Less is known about the biological 
characteristics of less common pLGGs which include, among others, gangliogliomas (GGs), 
dysembryoplastic neuroepithelial tumours (DNETs), and angiocentric gliomas (AGs).  
The location of pLGGs has a major impact on outcome since it determines the tumour’s 
resectability. Infratentorial pLGGs, which occur mainly in the cerebellum, can often be cured by 
surgery. Supratentorial tumours and those arising in the brainstem are much more difficult to resect, 
and residual or recurrent disease is, therefore, a common event. The latter are treated with 
radiotherapy or conventional chemotherapy (e.g. SIOP-LGG 2004 protocol). However, both 
treatments are associated with substantial long-term toxicity, and these tumours frequently evolve 
into chronic disease with high morbidity [2-6].  
The genomic landscape of pLGGs is now being defined. The most frequent genetic 
alterations are the KIAA1549-BRAF fusion gene and the BRAF V600E single point mutation [3]. Other 
mutations, such as FGFR1 alterations, are mainly expressed only by specific pLGGs subtypes, such as 
DNET [7]. Along with the dysregulated MAPK/ERK signalling mentioned above [8-10], aberrant 
activation of the PI3K/AKT signalling pathway, which can be demonstrated by high levels of 
phosphorylated AKT, is also a well-documented feature of gliomas, including pLGGs [3, 11, 12]. In 
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some cases, its dysregulation has been linked to genetic changes, such as BRAF fusions, FGFR1 
duplications and MYB rearrangements [3], or epigenetic modifications, but in many cases the 
mechanism underlying PI3K/AKT pathway activation is still unknown.  
MicroRNAs are emerging as major regulators of cancer-related gene expression. In this 
study, we examined the role of dysregulated microRNA expression in pLGGs, in particular in pLGGs 
arising in supratentorial areas of the brain, which have the poorest clinical outcomes. Our microRNA 
profiling analysis of a large series of grade I LGGs from paediatric patients pointed to the PI3K/AKT 
pathway as one of the most likely “targets” of dysregulated microRNA expression. In particular, we 
identified a novel microRNA-mediated mechanism that could be responsible for the hyper-activation 
of the PI3K/AKT signalling pathway. It involves the markedly down-regulated expression of miR-139-
5p, which was observed in the pLGG samples we analysed. Dysregulation of miR-139-5p has been 
linked to various types of cancer, including adult gliomas and paediatric high-grade gliomas (pHGGs) 
[13-15], but its role in pLGGs has not been investigated yet. Our functional studies in short-term 
cultures from primary supratentorial pLGGs indicate that the down-regulation of miR-139-5p in 
these tumours promotes PI3K/AKT pathway activation, thereby enhancing pLGG cell growth. 
 
Materials and Methods 
Unless otherwise stated, commercially available products were used according to the 
manufacturer’s instructions / protocols. 
 
Tumour samples and controls 
MicroRNA profiling was performed with quantitative PCR (qPCR) (as described below) on 
RNA extracted from snap-frozen tumour tissue samples from 45 patients (aged 1–16 years) with 
pLGGs. All underwent surgery at the Bambino Gesù Children’s Hospital in Rome or the Gaslini 
Institute in Genoa between 2014 and 2016. The clinical and pathological features of each case are 
summarized in Table 1.  
RNA and DNA used for the analyses were extracted from tumour samples with pathologist-
confirmed tumour cell contents of 80% or more. For control purposes, we profiled eight samples 
(three + a pool of five) of non-neoplastic brain tissue purchased from Ambion-Life Technology 
(Thermo Scientific, Wilmington, MA, USA) (n=1: AM7962, Human Brain Total RNA) or Biochain 
Institute (Newark, CA, USA) (n=7: R1234035-50, Total RNA-Human Adult Normal Tissue-Brain; 
R1234035-P, Total RNA-Human Adult Normal Tissue-5 Donor Pool-Brain; R1234035-50, Total RNA-
Human Adult Normal Tissue-Brain) and 28 samples (four + a pool of 24) of non-neoplastic brain 
cerebellum purchased from Biochain Institute (n=4: R1234039-50, Total RNA-Human Brain 
cerebellum) or Clontech Laboratories (Takara Bio USA Inc., Shiga, Japan) (n=1: 636535, Total RNA-
Human Brain cerebellum-24 Donor Pool-Brain). MicroRNA profiles for the pLGGs were also 
compared with profiles previously reported by our group for 13 pHGGs, which had been collected 
between 2005 and 2010 from patients aged from 3 to 17 years [15]. To ensure the comparability of 
these two cohorts, we re-analysed the microRNA profiles originally reported for the pHGGs [15] 
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using the same normalization procedure and statistical methods employed for comparing the pLGGs 
with healthy brain tissues, as reported below.  
For functional studies, we established short-term cultures of pLGG cells isolated from four 
primary tumours resected at Bambino Gesù Children’s Hospital (Rome) in 2016 (Table 2). We 
deliberately selected tumours with non-PA histology, since the biology of these pLGGs has been 
much less thoroughly explored than that of PAs. We also limited our analysis to supratentorial 
pLGGs, which are associated with lower miR-139-5p levels, lower resectability rates and worse 
outcomes than their infratentorial counterparts [11]. 
 
Histology  
Formalin-fixed paraffin-embedded (FFPE) samples of each of the 45 pLGGs used in the study 
were sectioned (3-μm) and stained with haematoxylin and eosin (H&E) for histology. All tumour 
diagnoses were then confirmed by consensus decision of 3 neuropathologists (F.G., M.A., and F.D.C.) 
using the WHO classification criteria [1].  
 
Immunohistochemistry 
Immunohistochemical studies were performed using anti-PIK3CA (Clinisciences, 
Nanterre, France), anti-phospho-p70 S6 kinase (Thr389) and anti-phospho-Akt (Ser473) (Cell 
Signalling Technology, Danvers, MA, USA). Paraffin-embedded slices of supratentorial 
pLGG tissues derived from the Pathology Department of the Bambino Gesù Children’s 
Hospital in Rome were used for the staining.  
For validation of PIK3CA, phospho-p70 S6 kinase (p-p70 S6K) and phospho-AKT (p-
AKT) immunohistochemical assay we tested positive tissues. Hepatocellular carcinoma 
samples were used for PIK3CA and breast cancer samples were used for p-p70 S6K and p-
AKT. For negative control primary antibody was omitted. For the evaluation of PIK3CA, p-
p70 S6K and p-AKT staining we used a scoring system. We considered: 0 for no staining; 1+ 
for barely perceptible staining; 2+ for light to moderate staining; and 3+ for moderate to 
heavy staining.  
 
RNA extraction of pLGG tissues and cells 
Please see Supplementary Materials and Methods for a detailed description. 
 
Analysis of BRAF status 
Each of the 45 pLGGs and the four patient-derived pLGG cell lines were analysed for the two 
most common genetic alterations found in these tumours—namely, the BRAF V600E point mutation 
(V600E) and the KIAA1549:BRAF fusion gene (including the three most frequent variants: KIAA1549-
BRAF exon 16-exon 9 [K16B9], KIAA1549-BRAF exon 16-exon 11 [K16B11], and KIAA1549-BRAF exon 
15-exon 9 [K15B9]).  
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BRAF fusion analysis was performed on tumour cDNAs with the Applied Biosystems Viia7 Real-Time 
quantitative PCR (RT-qPCR) System, as described by Tian et al. [16] and validated by PCR-based 
Sanger sequencing through amplification with specific pairs of primers flanking the fusion point 
between the KIAA1549 (in exon 15 or 16) and BRAF (in exon 9 or 11) genes, as described by Jones et 
al. [17]. The purified PCR products were sequenced on an ABI 3130 XL DNA analyzer (Applied 
Biosystems) using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) and the 
forward or reverse primer used to perform the PCR. The primer sequences were as follows: 
KIAA1549 exon 15: 5′-CGG AAA CAC CAG GTC AAC GG-3′; KIAA1549 exon 16: 5′-AAA CAG CAC CCC 
TTC CCA GG-3′; BRAF exon 9: 5′-CTC CAT CAC CAC GAA ATC CTT G-3′; BRAF exon 11: 5′-GTT CCA AAT 
GAT CCA GAT CCA TTC-3′. 
BRAF V600E mutation. DNA was extracted from fresh-frozen samples and patient-derived pLGG cell 
lines using the QIamp DNA Mini kit (Qiagen Inc., CA, USA). Quantity and quality were evaluated with 
a Nanodrop ND-1000 spectrophotometer (Thermo Scientific). RT-qPCR was performed, as described 
by Diniz et al. [18], using TaqMan probes (Life Technologies): BRAF_476_mu, which detects T>A 
transversion at position c.1799, and the reference-gene probe BRAF_rf. Threshold cycle (Ct) values 
were analysed using Mutation DetectorTM Software (Life Technologies). Genomic DNA extracted 
from BRAF V600E and BRAF wild-type colon cancer cell lines, kindly provided by Prof. Matilde Todaro 
(University of Palermo), were used as positive and negative controls, respectively. 
 
MicroRNA profiling and data analysis 
MicroRNA expression profiling was performed on the pLGG tumours using RT-qPCR with 
Taqman Low Density Array (TLDA) microfluidic cards (Human miR v3.0, Applied Biosystems), which 
detect the 754 best characterized members of the human microRNA genome. Each reverse 
transcriptase reaction was performed with specific primers according to Applied Biosystems 
protocols. The same method had been used to profile the pHGGs in [15]. 
Statistical analysis was performed with StatMinerTM software, v. 5.0 (Integromics TM). 
MicroRNA expression levels were normalized by using the global expression normalization method 
and the comparative threshold cycle method was used to calculate the relative microRNA 
expression. MicroRNAs with Ct values > 33 were excluded. Differential expression between groups 
was assessed with the Limma test, and p values < 0.05 were considered to be statistically significant. 
A single-assay qPCR for assessment of miR-139-5p expression (Code:002289) was carried out 
in triplicate using the TaqMan Individual microRNA assays (Applied Biosystems), as previously 
described [15]. Information regarding microRNA clusters was obtained from miRBase v.21 
(http://www.mirbase.org/) [19]. Validated targets of hsa-miR-139-5p were identified by 
interrogation of the miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/; [20]) and literature reports 
[13, 14].  
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MicroRNAs clustering analysis 
Dendrograms and heat maps were generated with the use of R (http://www.r-project.org/) 
using differentially expressed microRNAs as input. The Bray-Curtis method and the average linkage 
were used in hclust to cluster the samples and heatmap.2 to generate the heat maps [21]. 
 
DIANA mirPath analysis 
The microRNAs that were differentially expressed in pLGGs (vs. non-neoplastic brain tissue 
controls) were loaded into the DIANA mirPath tool (http://snf-515788.vm.okeanos.grnet.gr/) [22] 
for microRNA pathway analysis. MicroRNAs that were significantly dysregulated in the tumours were 
then analysed to identify their putative targets.  
 
Patient-derived primary pLGG cell cultures 
Culture and characterization. Human pLGG samples (described above) were collected immediately 
after resection and placed in Hank’s Balanced Salt Solution (HBSS) supplemented with 0.5% glucose 
and penicillin-streptomycin. The tissues were triturated with a serological pipette. DNAse I was 
added (final concentration 0.04%) and left for 20 min. Cell aggregates were then mechanically 
disrupted with pipettes of decreasing bore size. The single-cell suspension thus obtained was then 
centrifuged, and the cells suspended in NHA complete medium (Lonza, Basel, CH), counted and 
plated at a density of 160,000/mL. Prior to use in experiments, isolated primary pLGG cells 
underwent quality control assays to ensure they were reliable pLGG models. To this end, we verified 
that the BRAF status of each cell line was identical to that of the parent tumour (as described above 
in Analysis of BRAF status). For the three primary pLGG cells whose primary tumour did not show 
any genetic alteration on the BRAF gene, we compared methylation profiles to verify similarity 
between the primary cell line and the parental tumour. Immunofluorescence staining (described 
below) was used to confirm that the cells’ histotype-specific glial / neuronal cell biomarker profile 
was consistent with those described in the literature [23-25]. The percentage of senescent cells was 
also evaluated by staining for Senescence-Associated-β-galactosidase (SA-β-gal, described below). 
Cultures with SA-β-gal-positivity rates of 60% or more were excluded from experimentation. During 
the study, cells were discarded after a maximum of 8 passages (about 30 days of culture) or when 
SA-β-gal-positivity rates reached 60%. 
 
Cell treatments. Synthetic miR-139-5p (miRIDIAN microRNA code: C-310568-07, Dharmacon) or 
negative control (miRIDIAN microRNA negative control code: CN-001000-01, Dharmacon) were 
transfected into pLGG primary cells at 20 nM using HiPerFect transfection reagent (Qiagen Inc., CA, 
USA) for 48 h. miR-139-5p overexpression was confirmed by single assay qRT-PCR. For 
pharmacological inhibition of PI3K, LY294002 was purchased from Sellekchem, dissolved in DMSO, 
and stored until used in aliquots at -80°C as 50 mM stock solutions. LY294002 and CTRL (0.1% 
DMSO) were diluted in culture medium just before use. After 30 min of treatment with 50 μM 
LY294002, cells were shifted in normal culture medium for a recovery period of 48 h.  
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Cell growth was evaluated after 48 h by trypan blue exclusion assay. Specifically, the number of cells 
that did not take up trypan blue (viable cells) was counted both after transfection of synthetic miR-
139-5p or negative control. The number of cells that took up trypan blue (non-viable cells) was 
counted. Each sample was measured in triplicate and repeated at least three times.  
 
DNA Methylation Array Data Generation 
DNA methylation profiling using the Illumina Infinium HumanMethylation EPIC BeadChip array was 
performed according to the manufacturer’s instructions at the Genetics and Rare Diseases Research 
Division, Bambino Gesù Children’s Hospital, Rome, Italy. In detail 250 ng of DNA was used as input 
material for fresh-frozen tissue and primary cell line samples (after about 15 days of culture). t-
Distributed Stochastic Neighbor Embedding (TSNE) analysis was conducted as previously described 
[26]. Basic array processing and clustering analysis were performed using Illumina GenomeStudio 
V2011.1 (Methylation Module version 1.9.0, content descriptor version 1.2). 
(https://www.illumina.com/techniques/microarrays/array-data-analysis-experimental-
design/genomestudio.html ) (Illumina, Inc., San Diego, CA). Signal intensities were obtained without 
background subtraction and normalized to internal controls. Beta-values were used for downstream 
methylation analyses.  
 
Immunofluorescence studies 
Please see Supplementary Materials and Methods for a detailed description. 
 
Senescence-Associated-β-galactosidase activity 
SA-β-gal activity was assessed as described in Debacq-Chainiaux [28] with minor modifications. 
Briefly, cells were fixed with 3.6% of formaldehyde in PBS for 4 min at RT. Fixed cells were washed 
and incubated overnight with freshly prepared staining solution at 37°C in the absence of CO2. The 
cells were washed, and coverslips were mounted in antifade medium (Dako Fluorescence mounting 
medium, Agilent Technologies, Santa Clara, CA). Images were acquired using a Leica DM2500 
microscope (Leica Microsystems, Wetzlar, Germany) with a 20x/0.40 NA objective. Pictures were 
taken using the ISCapture software and processed with Adobe Photoshop (Mountain View, CA) to 
adjust brightness and contrast. The percentage of positive cells was evaluated by dividing the 
number of blue cells on the total number of cells in the field [8]. 
 
Western Blotting 
Please see Supplementary Materials and Methods for a detailed description. 
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Statistical Analysis 
Data reported in this paper are the means ± SD of at least three independent experiments 
each performed in triplicate. Unpaired t-test and Paired t-test were performed wherever 
appropriate using GraphPad Prism Software version 6.0 (CA, USA), p values < 0.05 were considered 
to be statistically significant. 
 
Results 
Characteristics of the pLGG cohort  
The clinical and pathological features of the 45 primary pLGGs we analysed are summarized 
in Table 1. Thirty (67%) of the tumours were pilocytic astrocytomas (PAs), eight (18%) were 
gangliogliomas (GGs), four (9%) were dysembryoplastic neuroepithelial tumours (DNETs), two (4%) 
were angiocentric gliomas (AGs), and one (2%) was a glioneuronal tumour (GNT). Patients’ age at 
diagnosis ranged from 1 to 16 years (median 7 years; mean 7.1 years). Three were located in the 
brain stem (two PAs, one GG). The other 42 included comparable numbers of infratentorial (n=25) 
and supratentorial (n=17) tumours. KIAA1549:BRAF fusion genes were common, in accordance to 
literature [3]. The K16B9 variant—the one most frequently encountered—was present in 18 (27%) 
pLGGs, most of which (13, 52%) were infratentorial. BRAF fusions were less common in the 
supratentorial tumours (5/18 [29%]). Three pLGGs harboured the BRAF V600E point mutation (two 
infratentorial and one supratentorial).  
 
MicroRNA profiles of pLGGs  
We measured the expression levels of 754 microRNAs in the 45 pLGGs described above and 
compared them with non-neoplastic brain (controls, CTRL). The results were also compared with 
profiles previously reported by our group for 13 pHGGs (glioblastoma multiforme, n=8; anaplastic 
astrocytoma, n=5) [15]. The TaqMan Low Density Array (TLDA) analysis reported similar high 
detection rates in all the three tissue groups (474 [63%] of the 754 microRNAs were identified in 
pLGGs, 436 [58%] in pHGGs, and 368 [49%] in controls). 
The differentially expressed microRNAs (Supplementary Tables 1 and 2) were plotted using 
hierarchical clustering, as reported in Fig.1. Some of the most striking alterations involved 
upregulation of microRNAs with documented oncogenic effects in many tumours (e.g., miR-21 and 
members of the miR-17-92 cluster [15, 30]) or down-regulation of microRNAs with reported 
oncosuppressive effects in various settings. The latter included miR-218 [31], miR-124 [30], miR-
487b [32], and miR-139-5p [33-37].  
We further evaluated the microRNAs profiles of supratentorial and infratentorial tumours with 
respect to non-neoplastic brain or normal cerebellum as controls (CTRL), respectively. Among 
supratentorial tumours, 69 microRNAs displayed significant tumour-related upregulation (n=28) or 
down-regulation (n=41) (p < 0.05) (Tables 3 and 4). Whereas in the analysis between infratentorial 
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tumours and normal cerebellum 109 microRNAs displayed significant tumour-related up (n=52) or 
down-regulation (n=57) (p < 0.05) (Supplementary Tables 3 and 4). 
Among dysregulated microRNAs, miR-139-5p was noteworthy since it was significantly down-
regulated only in supratentorial pLGGs (Table 4) and its down-regulated expression has been 
documented in high-grade gliomas (adult and paediatric) [13-15], but still unexplored in pLGGs. 
Interestingly, the number of differentially expressed microRNAs in pLGGs and pHGGs was 
lower than that observed when pLGGs were compared with non-neoplastic brain tissues 
(Supplementary Tables 5 and 6). The pLGG and pHGG samples segregated into two main clusters 
(Supplementary Fig. 1). The first (left side of Supplementary Fig. 1) comprised 19 of the 45 pLGGs. 
The second (right side of Supplementary Fig. 1) was more heterogeneous and contained two sub-
clusters: one contained 21 pLGGs, the second included both pLGGs and pHGGs. This finding 
highlighted the existence of a gradient of microRNA expression reflecting internal variation within 
the pLGGs cohort. Notably, the expression levels of miR-139-5p in pLGGs resembled those found in 
pHGGs. 
 
PI3K/AKT signalling is controlled by microRNAs that are dysregulated in pLGGs  
To explore the functional implications of the microRNA profile of our pLGGs cohort, we used 
the DIANA miRPath tool to identify signalling pathways likely to be vulnerable to the altered 
microRNA expression levels found in these tumours. As summarized in Table 5, after the broader 
category pathways in cancer, the PI3K/AKT pathway contained the highest number of components 
putatively targeted by the microRNAs dysregulated in our pLGG cohort. This finding is consistent 
with recent reports of aberrant PI3K/AKT/mTOR signalling in paediatric gliomas, both high- and low-
grade [11, 12]. This hyper-activation has been attributed to genetic and epigenetic alterations in 
certain glioma subsets, but in many cases the cause is still unknown. We noted with interest, 
therefore, that PIK3CA, which encodes the catalytic subunit of phosphatidylinositol 3–kinase (PI3K), 
is a validated target of miR-139-5p, as demonstrated by luciferase assay in Krishnan et al. [38]. The 
marked dysregulation of this tumour-suppressor microRNA in pLGGs was documented for the first 
time in our cohort (Supplementary Table 2 and Table 4). 
 
Downregulation of miR-139-5p in pLGGs favours tumour-cell proliferation 
Taken together, these findings suggested that down-regulation of miR-139-5p in 
supratentorial tumours might contribute to the development of pLGGs by de-repressing expression 
of PIK3CA, thereby favouring aberrant activation of the PI3K/AKT pathway. To address this 
hypothesis, we firstly investigated the expression of PIK3CA by performing immunohistochemistry 
assay in pLGG tissues derived from AG, DNET and GG tumours, which are predominantly 
supratentorial. As reported in Supplementary Figure 2, pLGGs showed positive staining for PIK3CA, 
with an average of 25% positive cells and a 2 +/3 + score. Then, we carried out in vitro experiments 
in primary monolayer cultures of pLGG cells isolated from patient-derived samples of AG, DNET, and 
GG. The characteristics of these cells are summarized in Table 2 and their growth curves and 
description are reported in greater detail in Figures 2 and 3 and Supplementary Figs. 3 and 4. The 
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immunofluorescence staining confirmed the glial and/or mixed neuro-glial nature of the primary 
pLGG cells. For all the histological types, cells were positive for the glial markers vimentin and S100, 
while the level of GFAP positivity was more variable ranging from 20 to 70%. In DNET and GG 
samples, we also detected frequent positivity for NeuN and Synaptophysin, neuronal markers, which 
conversely were absent in the AG. Therefore, the immunofluorescence staining together with the 
methylation profiling, a method to evaluate the similarity among tumours samples and their derived 
primary cells [10, 26, 39-41], indicate that our primary cells are a suitable and trustworthy model to 
study supratentorial pLGGs biology. 
MiR-139-5p levels in supratentorial pLGGs were markedly lower than those in non-neoplastic total 
brain tissues (Table 4, Fig. 4a). Downregulation of miR-139-5p was also evident in our patient-
derived primary pLGG cell cultures at levels comparable to those of the primary tumours they derive 
from (Fig. 4b). Overexpression of miR-139-5p in these cells (Supplementary Fig. 5) resulted in 
significantly reduced proliferation, which was evident in all three histological types represented (Fig. 
4c-f), while not affecting cell death (Data not shown).  
 
miR-139-5p controls PI3K/AKT/mTORC1 signalling in supratentorial pLGGs 
The results of the previous experiments provide evidence that down-regulation of miR-139-
5p plays a role in supratentorial pLGG cell growth. To determine whether its effects on cell growth 
were mediated by de-repressed PI3K activity, we assessed the effects of miR-139-5p overexpression 
on the phosphorylation of the PI3K target, AKT. At baseline, phosphorylated AKT (p-AKT) levels were 
high in all the cell cultures tested, but they dropped markedly after miR-139-5p overexpression (Fig. 
5a-c). In order to investigate whether miR-139-5p effect was directly mediated by PI3K inhibition, we 
examined proliferation and p-AKT levels in primary pLGG cells before and after treatment with the 
direct PI3K inhibitor LY294002. Our results showed that LY294002 treatment caused a significant 
impairment of cell proliferation (Fig. 5d-g) and decreased levels of phosphorylated AKT (p-AKT) 
(Fig.5h-j). Again, we did not observe any significant effect on cell death (Data not shown). 
One of the downstream effectors of PI3K/AKT signalling is mammalian target of rapamycin complex 
1 (mTORC1). Activation of this complex has already been reported in pLGGs [11], and hyper-
activation of the PI3K/AKT/mTORC1 axis has been implicated in the increased cell proliferation of 
these tumours [12]. We therefore wondered if mTORC1 inhibition was involved in the anti-
proliferative effects produced in pLGG cells by miR-139-5p overexpression. As shown in Figure 6a-c, 
cells transfected with miR-139-5p displayed significantly decreased phosphorylation of p70 S6K (p-
p70 S6K), a hallmark of mTORC1 activation. A comparable reduction was produced when PI3K was 
inhibited with LY294002 (Fig. 6d-f). Furthermore, immunohistochemical staining for p-p70 S6K and 
p-AKT were performed in pLGG samples. As reported in Supplementary Figures 6 and 7, tumours 
showed p-p70 S6K and p-AKT positive staining with an average of more than 10% positive cells and a 
score 2+ for both assay. Taken together, these data indicate that the down-regulated expression of 
miR-139-5p in primary supratentorial pLGG cells increases their proliferation by de-repressing 
PI3K/AKT signalling and that its effect is mediated by mTORC1, as summarized in Figure 7.  
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Discussion 
MicroRNAs have been identified as pivotal players in a variety of cancers [42, 43]. Thus far, 
however, the research conducted on these noncoding RNA species in pLGGs has been largely 
descriptive. Moreover, the conclusions that can be drawn from these studies are frequently limited 
by the small number of cases analysed [31, 44], the inclusion of high-grade gliomas besides pLGGs 
[45, 46] or the inclusion of adult patients [32].  
Our study differs from its predecessors in several respects. Our microRNA profiling study 
was conducted on fresh-frozen samples of 45 pLGGs, all of which were grade I tumours resected 
from patients 16 years of age or younger. We identified 93 microRNAs whose differential expression 
distinguished the pLGGs from controls. Since a number of microRNAs display directional and 
quantitative similar dysregulation in pHGG, these microRNAs are more likely to play a role in 
paediatric gliomas in general than in specific WHO classes of pLGGs. In fact, the down-regulated 
expression of miR-487b, miR-323a-3p, and miR-410—all members of the 379-656 cluster—has 
already been described in gliomas of various grades [32, 47, 48]. Likewise, upregulated expression of 
miR-18a-5p and miR-20a-5p (both belonging to the miR 17-92 cluster) and of miR-21-5p has been 
found in pLGGs [32] and pHGGs [15, 49, 50], as well as in other types of brain tumours [51-53]. 
Thanks to the results of this first part of the study we were able to identify specific microRNA 
profiles for pLGGs that will be object of future experimental investigations.  
The importance of the PI3K/AKT/mTOR pathway that emerged from our microRNA pathway 
analysis was not surprising. Along with the MAPK/ERK axis, it is one of the pathways most frequently 
upregulated in cancers, including pLGGs [2, 3, 54, 55]. Aberrant activation of PI3K/AKT/mTOR 
signalling in pLGGs has been reported in association with several genetic alterations, including BRAF 
fusions, FGFR1 duplications, and MYB rearrangements [3], which are present at different frequencies 
in the various pLGGs histologies, with the last two genetic alterations that have been more 
specifically detected in DNET and AG, respectively. Epigenetic mechanisms have been investigated as 
alternative activators of PI3K signalling in these tumours. For instance, promoter methylation and 
consequent silencing of expression of the gene encoding PTEN—a major negative regulator of PI3K 
signalling—has also been documented in some gliomas, and its frequency correlated positively with 
tumour grading [11, 56]. Therefore, PTEN promoter methylation, too, is unlikely to account for the 
oncogenic activation of the PI3K/AKT signalling in most grade I pLGGs. 
These considerations heightened our interest in the marked down-regulation of miR-139-5p, 
which was found in all examined grade I pLGGs. This microRNA has been demonstrated to be a 
validated negative regulator of the PIK3CA gene, which encodes the catalytic subunit of the PI3K 
[38]. The oncosuppressive effects of miR-139-5p have been described in a variety of solid tumours 
[37, 38, 57-59], including adult high-grade gliomas [13, 14]. Nonetheless, neither the level of 
expression of miR-139-5p or its biological role has never been explicitly investigated in pLGGs.  
Our functional characterization of miR-139-5p loss in grade I pLGGs provides the first 
evidence that this alteration may be a key driver of oncogenic activation of the PI3K/AKT/mTORC1 
pathway in these tumours. As illustrated in Fig. 7 the down-regulated miR-139-5p expression in 
supratentorial pLGGs significantly enhances activation of PI3K/AKT/mTORC1 signalling, as reflected 
by the high phosphorylation levels of AKT and p70 S6K, which dropped markedly after miR-139-5p 
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overexpression, and the biological outcome is a substantial increase in tumour-cell proliferation. 
MiR-139-5p down-regulation could conceivably act alone to activate this pathway. However, there is 
no reason to exclude the possibility of additive effects in the presence of the genetic and/or 
epigenetic mechanisms of activation discussed above. It is also important to recall that miR-139-5p 
down-regulation might produce additional tumour-promoting effects by depressing other targets, 
which include numerous genes with documented oncogenic effects in gliomas and in other cancers 
as well (e.g., FOS, HRAS, JUN, MCL1, NOTCH1, ELTD1, ZEB1 and ZEB2) [13, 14, 38, 57, 59-61].  
These conclusions are based on the results of studies on the restored expression of miR-139-
5p in primary cultures of patient-derived supratentorial pLGG cells, whereas the few functional 
studies conducted in this area have utilized immortalized pLGG cells, such as the PA-derived Res186 
line and/or Res259 cells, originally derived from a grade II diffuse astrocytoma [12, 62-64]. A major 
drawback of these cell lines is that they harbour genetic alterations that are relatively rare in pLGGs, 
and it is unclear to what extent they represent the primary lesions [12, 65, 66]. Previous attempts to 
use short-term primary cultures of patient-derived pLGGs have been hampered by markedly 
reduced growth secondary to Oncogene Induced Senescence (OIS) [8-10]. Protocol differences might 
contribute to explain why our efforts were more successful. It is worth noting, however, that the 
unsuccessful attempts cited above all involved the use of cells isolated from PAs, whereas the cells 
we used came from non-PA pLGGs. This choice was based on our purpose to elucidate the biology of 
pLGGs arising in supratentorial structures of the brain, where PAs are less common. Interestingly, 
however, we also encountered slow growth and senescence in our non-PA cultures (Supplementary 
fig. 3a-c). Senescence rates varied widely (even between cultures of cells representing the same 
pLGG histotype, data not shown), and they generally—but not always—increased over time. For 
instance, in some cultures, high rates were already observed after the first few passages. By carefully 
selecting the cultures destined for experiments particularly by analysing their whole genome 
methylation profile (Supplementary fig. 4), demonstrated to be a reliable method to pinpoint the 
identity of a broad range of brain tumours [10, 26, 39-41], but also continuously monitoring their 
senescence rates over time, we were able to complete short-term experiments and our assessment 
of these cells indicates that they are likely to provide reliable representations of the pLGGs seen in 
the clinic. Therefore our primary patient-derived pLGG cells present many benefits in comparison 
with the few immortalized cell lines that have been used until now and represent a more reliable 
model to study the biology of these tumours, that otherwise would be hardly addressed. The major 
disadvantage of these cultures is that they represent short-term cultures with a low proliferation 
rate and the number of experiments that can be performed is limited. Consequently, these primary 
models can be used only to answer to specific and well-defined biological questions. Interestingly, 
the methylation profiling allowed us to note that short-term primary cells could be more or less 
closer to their primary tumour, probably reflecting the heterogeneity of the cellular composition of 
the primary pLGG tumours analysed.  
Since morbidity and mortality, particularly due to disease progression, represent a significant 
problem in children affected by pLGGs even after many years from diagnosis [5, 6, 67] there is an 
urgent need for the identification and use of less toxic therapies, such as molecular targeted agents, 
in children with LGGs [67]. In this context, our primary patients’-derived cellular models represent a 
proper and trustable in-vitro model to test molecular targeted compounds.  
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In summary, the identification of miR-139-5p as a major regulator of the PI3K/AKT/mTORC1 axis in 
supratentorial pLGGs and the establishment of patients’-derived cellular models represent an 
important advancement and will open new perspectives to deepen the current knowledge on pLGGs 
biology.  
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Figure Legends 
 
Fig. 1 Hierarchical clustering of microRNAs displaying differential expression in pLGGs vs. 
non-neoplastic brain tissues (CTRL). Hierarchical clustering of the 93 microRNAs differentially 
expressed in pLGGs vs. CTRL (grey) (p<0.05) was performed and the Euclidean method was 
used to generate clusters on the basis of delta Ct values. Tissue: PA, pilocytic astrocytoma 
(blue); GG, ganglioglioma (red); GNT, glioneuronal tumour (purple); DNET, dysembryoplastic 
neuroepithelial tumour (orange); AG, angiocentric glioma (light blue). BRAF status was defined 
exclusively by the presence/absence of the V600E point mutation (green) and KIAA1549-BRAF 
fusion variants (yellow) (KIAA1549-BRAF exon 16-exon 9, KIAA1549-BRAF exon 16-exon 11, or 
KIAA1549-BRAF exon 15-exon 9). NEG, negative for all analysed mutations (black) 
 
Fig. 2 Immunofluorescence characterization of primary patient-derived pLGG cells. (a-c) 
Single-cell monolayers (on the average present after 7 days of culture) were subjected to 
immunofluorescence staining for glial markers (S100, vimentin, glial fibrillary acidic protein 
[GFAP]) and neuronal markers (NeuN, synaptophysin). In detail, (a) AG-derived cells (pLGG1) 
show positivity for glial markers only [23], whereas (b) DNET-derived cells (findings shown for 
pLGG2 are also representative of DNET line pLGG3) [24] and (c) GG-derived cells (pLGG4) 
expressed both glial and neuronal markers [25]. The positivity and negativity of the staining of 
the observed glial and neuronal markers was concordant with IHC staining results obtained by 
pathologists on FFPE samples of the tumours from which pLGG lines 1, 2, and 4 were derived 
(Data not shown). Scale bars, 50 μm and 100 μm (high magnification insert).  
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Fig. 3 Methylation analysis of primary patient-derived pLGG cells confirms their identity. 
DNA methylation profiling was performed on the three tumours (an AG and two DNETs) that 
did not show any genetic BRAF alterations and their primary pLGG derived cells. TSNE (t-
Distributed Stochastic Neighbor Embedding) analysis of the whole genome DNA methylation 
data show a close similarity between patient-derived pLGG cell lines, their primary tissues and 
the group of pLGGs they derive from (AG and DNET) but they diverge from other paediatric 
low-grade tumours and non-neoplastic cortex. pLGG1, AG tissue and patient-derived cells; 
pLGG2 and pLGG3, DNET tissues and their respective patient-derived cells (see Table 2). 
Colour legend of the TSNE plot as follows: PXA (brown); GG (orange); Cortex (light blue); AG 
(black); PA GG hemispheric (light purple); PA Infratentorial (purple); DNET (blue); PA midline 
(yellow). Abbreviations: AG, angiocentric glioma; DNET, dysembryoplastic neuroepithelial 
tumour; GG, ganglioglioma; PA, pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma. 
 
Fig. 4 Downregulation of miR-139-5p in pLGGs favours tumour cell-proliferation. (a-b) Single 
assay qPCR validation of downregulated miR-139-5p expression in (a) supratentorial pLGG 
tissues and (b) patient-derived primary pLGG cell lines and their corresponding tissues versus 
non-neoplastic total brain tissue (CTRL) (c-f) Effects on cell proliferation of miR-139-5p 
overexpression in cultured cells from (c) primary AG, (d) primary DNET indicated as pLGG2, (e) 
primary DNET indicated as pLGG3 and (f) primary GG. Cells were transfected with 20 nM miR-
139-5p or an empty vector (CTRL) and subjected to trypan blue staining 48 h later. Relative 
cell growth refers to fold over CTRL. * p<0.05 versus CTRL 
 
Fig. 5 PI3K/AKT signalling pathway inhibition decreases pLGG AKT phosphorylation and cell 
proliferation. (a-c) Phosphorylated AKT (p-AKT) and total AKT levels were measured in 
supratentorial primary pLGG cells transfected with miR-139-5p or empty vector (CTRL) (d-g) 
AG (d) pLGG2 (DNET) (e) pLGG3 (DNET) (f) and GG (g) cells were treated for 30 min with 50 
μM LY294002 and assayed for proliferation (Trypan Blue exclusion) after a 48 h recovery 
period in normal medium. (h-j) p-AKT and total AKT levels were measured in supratentorial 
primary pLGG cells treated with 50 μM LY294002 for 30 min or vehicle alone (CTRL) after a 48 
h recovery period in normal medium. Relative cell growth refers to fold over CTRL. * p<0.05, 
** p<0.001 versus CTRL 
 
Fig. 6 Phosphorylation of p70 S6K in pLGG cells subjected to miR-139-5p overexpression or 
LY294002 treatment. The overexpression of miR-139-5p (a-c) and direct PI3K inhibition for 30 
min with 50 μM LY294002 followed by a 48 h recovery period in normal medium (d-f) both 
strongly reduced p70 S6K phosphorylated levels (p-p70 S6K) while leaving unaffected the level 
of total p70 S6K. 
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Fig. 7 Downregulation of miR-139-5p expression in pLGGs promotes proliferation by de-
repressing PI3K/AKT/mTORC1 signalling. miR-139-5p, that targets the 3’-UTR of PIK3CA, is 
strongly downregulated in pLGG tumours resulting in the hyper-activation of the PI3K/AKT 
pathway. After miR-139-5p overexpression in pLGG primary cells both AKT and p70 S6K 
phosphorylation levels are reduced, with a consistent significant impairment in cell 
proliferation. PTEN, phosphatase and tensin homolog; PI3K, phosphatydil-inositol-3-kinase; 
PDK-1, phosphoinositide-dependent kinase 1; TSC2, tuberous sclerosis complex 2; Rheb, Ras 
homolog enriched in brain; mTORC1, mammalian target of rapamycin 1; p70 S6K, p70 S6 
kinase.  
 
Supplementary Figure Legends 
 
Supplementary Fig. 1 Hierarchical clustering of microRNAs displaying differential expression 
in pLGGs vs. pHGGs Hierarchical clustering of the 60 microRNAs differentially expressed in 
pLGGs vs. pHGGs. The Euclidean method was used to generate clusters based on delta Ct 
values. Tissue: PA, pilocytic astrocytoma (blue); GG, ganglioglioma (red); GNT, glioneuronal 
tumour (purple); DNET, dysembryoplastic neuroepithelial tumour (orange); AG, angiocentric 
glioma (light blue); pHGG, paediatric high-grade gliomas (brown)  
 
Supplementary Fig. 2 Expression of PIK3CA in pLGG tissues. (a) Top: Representative images of 
immunohistochemical (IHC) staining for PIK3CA in AG, DNET and GG show positive staining in 
cytoplasm of neoplastic cells. Bottom: Negative control performed omitting primary antibody. 
(b) Left: Representative images of hepatocellular carcinoma sample used as positive control 
used for PI3KA imuunohistochemical assay. Right: Negative control was performed omitting 
primary antibody. Scale bars: 20 μm. Original magnification ×20. 
 
Supplementary Fig. 3 Expression of the senescence marker SA-β-gal in patient-derived 
primary pLGG cells. Representative images of SA-β-gal expression in two of the primary cell 
cultures used in the study: (a) pLGG4 cells derived from a GG and (b) pLGG2 cells from a DNET. 
Both displayed low SA-β-gal-positivity rates (less than 20%). In contrast, in panel (c) a 
representative image of pLGG4 at passage 12 is reported. The very low proliferation rate and 
high percentage of SA-β-gal-positive cells reached by these cells rendered them unsuitable for 
further biological investigations. Scale bar, 100 μm. (d) Growth curves of patient-derived 
primary pLGG cells from T0 until passage 8 (ps8); pLGG1 cells derived from an AG (blue), 
pLGG2 cells from a DNET (green) and pLGG4 cells derived from a GG (orange).  
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Supplementary Fig. 4 Methylation profile and copy number variation (CNV) of primary 
patients’ derived pLGG cells shows a close similarity to the primary tumour. (a) 
Unsupervised hierarchical clustering of the whole genome DNA methylation data performed 
by using Illumina GenomeStudio V2011.1 showed a close similarity between the primary 
tumours and their corresponding cells. This result indicates that the innate methylation profile 
of the cell of origin was unaffected from the process of in vitro culture. (b) CNV analysis shows 
chromosome 1 to 22 (and X/Y if automatic prediction was successful). Gains/amplifications 
represent positive - green, losses negative-red deviations from the baseline. 29 brain tumour 
relevant gene regions are highlighted for easier assessment. (see, 
http://www.bioconductor.org/packages/devel/bioc/html/conumee.html). A specific genetic 
alteration is highlightened (red arrow) when present. 
pLGG1 primary cells derive from an AG tumour (see Table 2), pLGG2 and pLGG3 primary cells 
derive from two DNET tumours (see Table 2). Abbreviations: AG, angiocentric glioma; DNET, 
dysembryoplastic neuroepithelial tumour 
 
Supplementary Fig. 5 Levels of miR-139-5p before and after its overexpression in the four 
primary pLGG cell lines (derived from an AG, two DNETs, and a GG). Cells were transfected 
with 20 nM miR-139-5p and assayed 48 h later. (a) MiR-139-5p level in non-neoplastic brain 
tissues (CTRL) was 68-fold higher than that found in the pLGG cells at baseline. (b-d) Post-
transfection assays of (b) AG cells, (c) DNET cells, and (d) GG cells revealed mean miR-139-5p 
levels approximately 30-fold higher than those found at baseline (CTRL). * p<0.05, *** 
p<0.001 versus indicated CTRL 
 
Supplementary Fig. 6 Expression of p-p70 S6K in pLGG tissues. (a) Top: Representative images of 
cytoplasmic immunostaining for phospho-p70 S6 kinase (p-p70 S6K) in AG, DNET and GG 
samples. Bottom: Negative control was performed omitting primary antibody. (b) Left: Human 
breast cancer was used as positive control for p-p70 S6K staining. Right: Negative control was 
performed omitting primary antibody. Scale bars: 20 μm. Original magnification ×20. 
 
Supplementary Fig. 7 Expression of p-AKT in pLGG tissues. (a) Top: Representative images of 
supratentorial pLGG samples showing positive staining for phospho-AKT (p-AKT). Bottom: 
Negative control was performed omitting primary antibody. (b) Left: Human breast cancer was 
used as positive control to detect p-AKT immunopositivity. Right: Negative control was 
performed omitting primary antibody. Scale bars: 20 μm. Original magnification ×20. 
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